Market Place
Sourcing Support
Arch Oncology Receives U.S. FDA ODD for AO-176 in Multiple Myeloma
21 Jan 2022 //
GLOBENEWSWIRE
Arch Oncology Strengthens Medical and Clinical Leadership Teams
02 Aug 2021 //
GLOBENEWSWIRE
Arch Oncology goes on hiring spree from AbbVie, BMS, Xencor
02 Aug 2021 //
FIERCEBIOTECH
Arch Oncology Secures $105 Million Series C Financing
27 Apr 2021 //
PRESS RELEASE
Arch Oncology Announces Two New Preclinical Data Presentations
11 Mar 2021 //
GLOBENEWSWIRE
Arch Oncology to Collaborate with Merck on Ph 1/2 Trial of Anti-CD47 Antibody
09 Feb 2021 //
ARCHONCOLOGY
Arch Oncology Announces First Patient Dosed in Phase 1/2 Clinical Trial
07 Dec 2020 //
GLOBENEWSWIRE
Arch Oncology Appoints Ronald Krasnow, Esq. as Chief Operating Officer
16 Nov 2020 //
BIOSPACE
Arch Oncology to Present New Preclinical Data on Highly Anti-CD47
09 Nov 2020 //
BUSINESSWIRE
Arch Oncology Advances Anti-CD47 Antibody AO-176 Chemotherapy Combo Ph 1/2 Trial
05 Oct 2020 //
BUSINESSWIRE
ARCH’s Bob Nelsen is backing an mRNA upstart
23 Sep 2020 //
ENDPTS
A fourth revolution in cancer therapies, ARCH-backed Boundless Bio flashes
19 Sep 2019 //
ENDPOINT NEWS
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.